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Introduction
Hirschsprung’s disease (HSCR), also called aganglionic
megacolon, is a hereditable disease of the enteric nerv-
ous system.1,2 It is an embryonic developmental disor-
der characterized by the absence of ganglion cells which
are derived from the neural crest in the lower digestive
tract. Due to the absence of enteric plexus, gut motility
is seriously compromised in HSCR patients, resulting in
intestinal obstruction. There is a racial and ethnic vari-
ation in the prevalence of HCRS, and it is more often
found among Asians as compared with Caucasians (2.8 vs.
2 per 10,000 live births). About 20% of HSCR cases
are familial ones, with considerable genetic diversity in
HSCR arising either because of locus or allelic hetero-
geneity. Studies of the genetic bases of HSCR have
identified several disease-causing genes, including
RET (receptor tyrosine kinase, 10q11.2),3–7 GDNF
(glial cell derived neurotrophic factor, 5p12-3.1),8,9
NTN (neurturin, 10q13.3),10 EDN3 (endothelin 3,
20q13.2),11 and EDNRB (G protein-coupled–
endothelin receptor B, 13q22).12 In the case of RET
mutation in several families, the HSCR phenotype was
found to cosegregate with MEN2A, particularly when
the RET gene mutation is in codon 618 or 620.3 Thus,
the clinical manifestations of RET mutations are highly
dependent on the location of the mutation.
Heterozygous germline mutations in the RET gene
that act as dominant inhibitors account for around 50%
of familial HSCR and 7–35% of sporadic HSCR.5,7,13,14
These mutations include missense, nonsense, deletion,
insertion and frameshift mutations and occur through-
out the RET gene.5,7,13–15 Most missense mutations
result in RET inactivation, therefore implying that
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HSCR is due, in part, to the loss of RET function or a
reduced amount of RETprotein. Previous studies found
the prevalence of RET gene mutations among patients
with sporadic HSCR to be 14.3% in Japanese16 and 19%
in southern Chinese.15 In contrast, the prevalence of
RET gene mutations among patients with sporadic
HSCR has been reported to be as low as 3.6% in
Taiwan,17 far below the global average. To address
this discrepancy, we investigated the RET gene in 15
Chinese with HSCR in Taiwan.
Methods
Patients
Fifteen unrelated Han Chinese (9 males, 6 females;
age range, 2–21 years) with sporadic HSCR were stud-
ied. Some of them have been described in a previously
published report.18 The clinical diagnosis of HSCR was
based on previously described criteria.2 An additional
50 unrelated normal Han Chinese subjects were re-
cruited as controls to determine whether any sequence
changes might be a common polymorphism. Demo-
graphic data and a detailed family history were obtained
by an interview with each patient and their family
members. This study was approved by the institutional
review board of the hospital, and informed consent
was obtained from each individual.
Analysis of the RET gene
Genomic DNA was isolated from EDTA-preserved
whole blood using the GFX Genomic Blood DNA
purification kit (Amersham Biosciences, Piscataway,
NJ, USA). The 21 coding exons of the RET gene were
amplified by polymerase chain reaction using primers
and conditions as described previously16,19,20 or mod-
ified empirically (Table 1). For all reactions, a 25-µL
reaction mixture contained 200 ng of genomic DNA,
2.0 mM MgCl2, 0.2 mM of each dNTP, 0.15 µM of
each primer, 1× reaction buffer and 1 unit of FastStart
Taq DNA polymerase (Roche, Indianapolis, IN, USA).
PCR products were purified by spin column using the
GFX PCR DNA and Gel Band Purification Kit
(Amersham Biosciences) and sequenced by automated
DNA sequencing analysis with fluorescence-labeled
dideoxyterminators (BigDye Terminator V3.1 Cycle
Sequencing Kits, Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s instructions
(ABI 377-36 Autosequencer; Applied Biosystems).
Mutation confirmation
We used restriction analysis to confirm the presence of
mutations in the RET gene. Restriction endonucleases
were selected on the basis of whether a mutation created
or destroyed a restriction endonuclease site. Digested
PCR products were analyzed by electrophoresis on
12.5% polyacrylamide gels with fragments visualized
Table 1. Oligonucleotide primers used for PCR amplification, PCR product sizes and annealing temperatures
Exon Forward primer Reverse primer Product size (bp) Annealing temperature (°C)
1 GGGCGGCCAGACTGAGCGC AACTTCGCCCTGGCCCTGCGG 207 67
2 AGCCTTATTCTCACCATCCC ATAAGGGCGGCTTGAGGAAG 373 56
3 GGTTTACACCAGCCCTGGAG TGTGTCAAGGGCTCGCAGAG 456 56
4 CTTCCCGAGGAAAGCGGCTG CACGGACACTAAACCGACCG 393 56
5 CATCCTAAGGTCTCTGGTTTT GAGCGAGCACCTCATTTCCT 331 56
6 CAGAGCAGCTTGGTGGTCA AGTCTACTCTGTGCTGGTTGG 349 56
7 GAATCTCTACCCTCAGGCCATT ACCCTCCCTCCCTGGAG 358 56
8 GCACTAGCTGGACGCTGG GAGACCATCCCAGGCTGGC 280 67
9 TAGAGGGGCAGGATCTGC GCAACTCTGGCTGAAGTGC 282 67
10 AGAGAATGGTCAGTAGGGACACT GGACCTCAGATGTGCTGTT 531 56
11 ATGAGGCAGAGCATACGCAG AACGGCACCTCATCACAGTC 535 56
12 CTTTTCCCCCCTCTTCTCC GCATTGGGGGCTCTTCAGGGT 293 56
13 GCAGGCCTCTCTGTCTGAACTT GGAGAACAGGGCTGTATGGA 296 56
14 TGTGTCCACCCCCTTACTCATTGG CGTGGTGGGTCAGGGTGTGG 399 67
15 CCCCCGGCCCAGGTCTCAC GCTCCACTAATCTTCGGTATCTTT 358 56
16 CCTCCTTCCTAGAGAGTTAG CCCCACTACATGTATAAGGG 191 56
17 GGCTCTGTGAGGGCCAGGT CCCTTCCCAAGTGAGGCT 232 56
18 GGCTGTCCTTCTGAGACC ACTGCCCTGGGGTGAGGCT 233 56
19 TAGTTGTGGCACATGGCTTG CAGAGCAGACTTTGGTTTTG 313 56
20 TGCACTTGAAGTTTTGGTTCTT CTCAGAGCTCTTACCCGGTGT 439 56
21 CCGGGCCCACCACATCATC AGCCCAAATTAGAGCCAGGTTACG 835 56
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by a silver staining kit (Amersham Pharmacia Biotech
AB, Uppsala, Sweden). If the mutation neither created
nor destroyed any restriction endonuclease site, we se-
quenced 50 unrelated normal subjects to study whether
the DNA variation was a common polymorphism.
Results
The clinical features, pathologic findings and mutational
analyses of all the individuals are shown in Table 2
and Figure 1.
We identified heterozygous missense mutation in
the RET gene in 2 of 15 patients. The mutations
found were a point mutation in exon 2 (CGCCAC)
resulting in a substitution of arginine by histidine at
codon 67 (patient 1) and a point mutation in exon 3
(TAC AAC) resulting in a substitution of tyrosine
by asparagine at codon 146 (patient 2). The patholog-
ical finding disclosed short-segment HSCR in patient
1 and long-segment HSCR in patient 2. The R67H
mutation neither created nor destroyed any restric-
tion endonuclease site, so we sequenced 50 normal sub-
jects and found that it is not a common polymorphism.
The Y146N mutation destroys the restriction site for
AccI. The D489N variation in family 3 was consid-
ered to be polymorphic as in D571N variation, which
has been reported in 7% of individuals in a Korean
population.21
There were no relationships between the specific
mutations with clinical features of HSCR disease (sex,
age at onset, length of anatomic involvement).
Discussion
The R67H mutation that we identified in patient 1 has
been previously reported in a 5-year-old Japanese girl
with central hypoventilation syndrome, chronic intes-
tinal pseudo-obstruction and intractable hypoglycemia
Table 2. Clinical summary and mutational analyses for all studied subjects
Proband Sex Age Age at onset Operative finding Mutation
1 F 7 yr 4 yr Short segment Exon 2, R67H (CGCCAC)
2 F 2 yr 9 mo Long segment Exon 3, Y146N (TAC AAC)
3 M 2 yr 9 mo Short segment Exon 9, D489N (GAT AAT)*
4 M 17 yr 16 yr Long segment
5 M 3 yr 2 yr Long segment
6 M 4 yr 4 mo Short segment
7 F 5 yr 1 mo Long segment
8 F 5 yr 1.5 mo Short segment
9 M 6 yr 1.5 mo Short segment
10 M 11 yr 1.5 mo Short segment
11 M 21 yr 3 yr Short segment
12 M 8 yr 3 yr Short segment
13 M 4 yr 2 yr Short segment
14 F 6 yr 1 mo Short segment
15 F 9 yr 1 yr Long segment
*Considered to be a polymorphism. Short segment HSCR involves the rectum and the sigmoid colon only, while long segment HSCR extends toward the proximal
end of the colon.
I
II
336 bp 
264 bp 
120 bp 
72 bp 
N/M
N/N N/N
Y146N
Figure 1. Pedigree of family 2 with RET gene mutation. Affected
patients are indicated by black symbols. Normal individuals are
indicated by white symbols. The arrow indicates the proband. The
RET genotype of each individual is indicated below each symbol:
N = normal allele; M = mutant allele. The size of the PCR product
of family 2 (Y146N) is 456 bp. After AccI treatment, 3 restriction
products of 264 bp, 120 bp and 72 bp in the normal type and 2
restriction products of 336 bp and 120 bp in the Y146N mutant
were produced.
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in infancy,22 and is not present in the normal 
population. Thus, R67H in the RET allele is likely to
be disease-causing.
Patient 2 had a novel heterozygous mutation at
codon 146 of exon 3 (TAC AAC) that resulted in a
substitution of tyrosine by asparagine. Evidence that
the Y146N mutation was related causally to HSCR in
this patient is based on the following: (1) the Y146
residue is highly conserved in human, chimpanzee, dog,
rat, mouse, and chicken RET genes, suggesting that
substitutions at these codons are not tolerated; (2) this
base change was not found in 50 unrelated subjects,
suggesting that it is not a common polymorphism; (3)
the amino acid changes from hydrophobic amino acid
to polar amino acid with an uncharged R group. Since
both parents of patient 2 were normal in both pheno-
type and genotype, this mutation most likely arose de
novo in this subject. The R67H and Y146N mutations
resulted in short-segment and long-segment HSCR,
respectively. Both mutations alter amino acids that are
in the extracellular portion of the RET proto-oncogene.
Amino acid substitution in the extracellular domain
(class I mutation) has been predicted to impair RET
maturation and prevent protein from reaching the cell
surface,23 and might alter protein folding and cause
inappropriate intracellular trafficking.24,25 However,
there does not appear to be a significant relationship
between the specific missense mutations or their loca-
tion with specific clinical features of HSCR disease (sex,
age of onset, length of anatomical involvement) in this
or another study.15
In contrast with the low frequency of RET gene
mutations previously observed in patients with HSCR
disease in Taiwan,17 we found a more typical prevalence
(13.3%) of RET mutations in this study despite the
small number of subjects analyzed. This discrepancy
probably reflects an ascertainment bias. Compared with
the RET gene mutations in southern Han Chinese
with HSCR,15 we found no similar mutations in the
Han Chinese in Taiwan.
In conclusion, we have identified 2 missense
mutations in the RET gene in 15 patients with HSCR
disease in Taiwan. The Y146N mutation we identified
was novel.
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